• HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
Type and hit ENTER
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
GET CONNECTED
  • HOME
  • ABOUT US
    • CAREERS
  • TECHNOLOGY
  • NEWS
  • SERVICES
    • RESEARCH AND DEVELOPMENT
  • PRODUCTS
    • My account
    • Cart
  • CONTACT
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference
Share
ProteaseTag®

ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference

October 30, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the North American Cystic Fibrosis Conference, which takes place between November 1st – 5th in Indianapolis. Dr Charlene Robb will be presenting a poster entitled “Do sputum storage conditions impact on the quantification of active neutrophil elastase, interleukin-8, interleukin-6 and tumour necrosis factor-α?” on Thursday November 2nd between 11.15am and 1.45pm (Poster Number 288).

In addition, the team at the Royal Brompton Hospital in London, one of the largest CF expert centres in Europe, will be presenting the first data on the use of the ProteaseTag® Active NE Immunoassay to measure active neutrophil elastase in exhaled breath condensate:

Active Neutrophil Elastase can be detected in Exhaled Breath Condensate in patients with Cystic Fibrosis

C74-ADVANCES IN TRANSLATIONAL COPD

Thematic Poster Session

TUESDAY, MAY 23, 2017

9:15 AM – 4:15 PM

Jane Davies, Professor in Paediatric Respirology & Experimental Medicine at the National Heart and Lung Institute and an Honorary Consultant in Paediatric Respiratory Medicine at the Royal Brompton & Harefield NHS Foundation Trust, said ”To our knowledge this is the first study to report NE in EBC in CF patients; whilst the method requires further optimisation, we believe this could be a promising avenue for monitoring of patients at early stages of disease, such as children.”

Dr David Ribeiro, CEO of ProAxsis, said: “This is the 31st annual NACF Conference, which brings together scientists, clinicians and caregivers from around the world to discuss and share ideas on the latest advances in CF research. The work by Dr Robb and colleagues provides further data for researchers conducting clinical trials worldwide who need to collect, transport and analyse sputum samples for inflammatory biomarkers such as active neutrophil elastase. The 19-patient study conducted at the Royal Brompton Hospital opens up the possibility of utilising the ProAxsis technology for airway monitoring in patients unable to expectorate sputum. We believe these latest findings on our ProteaseTag® technology will be of great interest to the CF community. ”

To find out how ProAxsis can support the measurement of active protease biomarkers of disease, or for any further queries, please contact info@proaxsis.com.

October 30, 2017

Related News

Other posts that you should not miss.
News, ProteaseTag®

ProAxsis abstracts at 2017 European Respiratory Society Conference

September 6, 2017
-
Posted by Webmaster

ProAxsis will be presenting further data on its ProteaseTag® technology, at the European Respiratory Society Conference, which takes …

Read More
September 6, 2017
Posted by Webmaster
Conferences, NEATstik®, ProteaseTag®

ProAxsis Presenting New Data on NEATstik and New High Sensitivity Neutrophil Elastase Immunoassay at ATS 2018

May 2, 2018
-
Posted by David Ribeiro

ProAxsis confirms that new data on its ProteaseTag® technology will be presented at the American Thoracic Society …

Read More
May 2, 2018
Posted by David Ribeiro
Conferences, Neutrophil Elastase Immunoassay, News, ProteaseTag®

ProAxsis’ ProteaseTag® NE Immunoassay highlighted at BTS 2016

December 8, 2016
-
Posted by Webmaster

ProAxsis (www.proaxsis.com) was delighted to observe that measuring active neutrophil elastase (NE) by its ProteaseTag® Active NE Immunoassay …

Read More
December 8, 2016
Posted by Webmaster
← PREVIOUS POST
ProAxsis provides update on commercialisation progress
NEXT POST →
ProAxsis to test ProteaseTag® Technology in Cystic Fibrosis and Chronic Obstructive Pulmonary Disease at National Jewish Health
Categories
  • Announcements
  • Conferences
  • NEATstik®
  • Neutrophil Elastase Immunoassay
  • News
  • ProteaseTag®
  • Trials
  • Video
GET CONNECTED
RECENT POSTS
  • ProAxsis Limited appoints first distributor for DACH region
    December 14, 2020

    ProAxsis Limited (www.proaxsis.com), the Belfast-based diagnostics company specialising in the measurement of active …

  • ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
    December 10, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based respiratory diagnostics company, today announces that it has been …

  • ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
    December 2, 2020

    ProAxsis (www.proaxsis.com), the Belfast-based protease diagnostics company, is delighted to announce that it …


ProAxsis Ltd
Unit 1B, Concourse Building 3,
Catalyst Inc,
Queen’s Road, Titanic Quarter,
Belfast,
BT3 9DT,
Northern Ireland

tel +44 (0)28 9073 0444
email info@proaxsis.com

RECENT NEWS
  • December 14, 2020
    ProAxsis Limited appoints first distributor for DACH region
  • December 10, 2020
    ProAxsis Limited supported by Innovate UK to accelerate work on inflammatory biomarkers associated with COVID-19
  • December 2, 2020
    ProAxsis Limited recognised as Gold Level Innovator by Innovate NI
LATEST TWEETS
Twitter
ProAxsis
Follow Me
ProAxsis is delighted to have received this support from Innovate UK - https://t.co/toTxOz9KK6
46 days ago
- ProAxsis
RT @GRobinsonDUP: I’m delighted that @ProAxsis based in East Belfast have been successful in their application for an Innovate UK Grant, wh…
46 days ago
- ProAxsis
We are delighted to announce that as of today, we have appointed an exclusive distributor for our portfolio of prod… https://t.co/rmCmIugsLa
67 days ago
- ProAxsis
Due to our continued expansion, we wish to recruit an Administration Officer. This post can be full-time or part-ti… https://t.co/k3wKwVfOKy
87 days ago
- ProAxsis
Copyright © 2016-2018 - ProAxsis - All rights reserved. 
ProAxsis to showcase ProteaseTag® abstracts at 2017 North American Cystic Fibrosis Conference | ProAxsis